Vol. 2 No. 10 (2022)
Reimbursement Reviews

Ruxolitinib (Jakavi)

Published October 21, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Ruxolitinib (Jakavi), tablet 5 mg, 10 mg, 15 mg, 20 mg, oral.
  • Indication: For the treatment of chronic GvHD in adults and pediatric patients 12 years and older who have inadequate response to corticosteroids or other systemic therapies.